Gland Pharma
Ticker > Company >

Gland Pharma share price

Gland Pharma Ltd.

  2.59 L   752   134 NSE: GLAND BSE: 543245 SECTOR: Pharmaceuticals & Drugs

2970.20
+2.60 (0.09%)
NSE: 14 Aug 4:00 PM

Buy on Angel One

Price Summary

Today's High

₹ 3039.8

Today's Low

₹ 2946.6

52 Week High

₹ 3039.8

52 Week Low

₹ 1573.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 48998.4 Cr.

Enterprise Value

₹ 45820.76 Cr.

No. of Shares

16.5 Cr.

P/E

35.13

P/B

4.4

Face Value

₹ 1

Div. Yield

0.67 %

Book Value (TTM)

₹  674.62

CASH

₹ 3177.64 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

51.77 %

EPS (TTM)

₹  84.54

Sales Growth

10.59%

ROE

12.67 %

ROCE

17.18%

Profit Growth

19.25 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Gland Pharma Ltd.

Acris Chlostin Cutenox Cutinorm Glanpan Heplock Hep 5 Larinox Tezcort Glanikinase

Index Presence

The company is present in 29Indices.

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
52024.15
  -374.949999999997 (-0.715565725365508%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
51916.95
  -362.200000000004 (-0.692819221429586%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
48396.9
  -225.049999999996 (-0.462856796158928%)

NIFTYMNC

Nifty MNC
33626.45
  -116.950000000004 (-0.34658629539408%)

NIFTYPHARMA

Nifty Pharma
26445.55
  -241.25 (-0.904004976242934%)

NIFTY500

Nifty 500
23594.9
  -63.1999999999971 (-0.267138950296075%)

NFT500HEALTH

Nifty500 Healthcare Index
21558.8
  -90.2999999999993 (-0.417107408622064%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
21549.35
  -107.400000000001 (-0.495919286134816%)

NFTMIDSML40050:50

Nifty MidSmallcap400 50:50
20993.8
  -103.5 (-0.490584103179081%)

NFTSMALL500

Nifty Smallcap 500
20858.4
  -64.7999999999993 (-0.309704060564342%)

NIFTYSMALL

NIFTY Smallcap 100
19738.55
  -136.549999999999 (-0.68704056834934%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18703.65
  -71.5499999999993 (-0.381087817972636%)

NIFTYSMALLCAP250

Nifty Smallcap 250
18278.8
  -87.1000000000022 (-0.474248471351812%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
17011.85
  -84.0500000000029 (-0.491638346036205%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16724
  -54.6500000000015 (-0.325711544134966%)

NFT500EQUAL

Nifty 500 Equal Weight
15112.05
  -63.8500000000004 (-0.420732872514973%)

NIFTYTOTALMCAP

NIFTY Total Market
13324.85
  -33.6499999999996 (-0.251899539618972%)

NIFTYSMALLCAP50

Nifty Smallcap 50
9873.95
  -69.25 (-0.696455869337842%)

NIFTY100ESG

NIFTY100 ESG
5090.8
  -8.84999999999945 (-0.173541321463222%)

BSE HC

Bse Healthcare
50975.98
  -58.2199999999939 (-0.114080361796587%)

MIDCAP

Bse MidCap
44246.27
  -699.210000000006 (-1.55568479856041%)

BSE500

Bse 500
36962.93
  -61.5199999999968 (-0.166160469635601%)

MSL400

Bse 400 MidSmallCap Index
12891.56
  -38.75 (-0.29968345693181%)

S&P MIDSMLCAP

Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

BSE1000

Bse 1000
11072.45
  -17 (-0.15329885612001%)

S&P LARGEMIDCAP

Bse LargeMidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SML250

Bse 250 SmallCap Index
7216.68
  -30.9899999999998 (-0.427585693057209%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.59%
3 Year7.97%
5 Year5.62%

Profit Growth

1 Year19.25%
3 Year18.76%
5 Year5.44%

ROE%

1 Year12.67%
3 Year12.2%
5 Year13.1%

ROCE %

1 Year17.18%
3 Year16.57%
5 Year17.71%

Debt/Equity

0

Price to Cash Flow

43.16

Interest Cover Ratio

97.7361

CFO/PAT (5 Yr. Avg.)

0.830912941532411

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 51.77 0.00
Mar 2026 51.83 0.00
Dec 2025 51.83 0.00
Sep 2025 51.83 0.00
Jun 2025 51.83 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 18.7616800389937% for the Past 3 years.
  • The company has significantly decreased its debt by 2.551 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 97.7361.
  • The Company has been maintaining an effective average operating margins of 33.5755161979936% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 10.1453.
  • The company has a high promoter holding of 51.77%.

 Limitations

  • The company has shown a poor revenue growth of 7.97073718241694% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 1038.84 1074.15 1177.51 1261.59 1286.64
Total Expenditure 679.99 699.27 755.89 753.88 813.13
Operating Profit 358.85 374.89 421.63 507.72 473.51
Other Income 54.74 82.59 60.21 106.36 58.82
Interest 7.44 3.97 0.5 6.17 0.69
Depreciation 43.77 44.84 44.53 43.11 43.95
Exceptional Items 0 0 -24.35 0 0
Profit Before Tax 362.38 408.67 412.46 564.8 487.69
Tax 93.13 106.68 104.61 144.35 123.3
Profit After Tax 269.26 302 307.85 420.45 364.39
Adjusted EPS (Rs) 16.34 18.33 18.68 25.52 22.09

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 4400.71 3616.53 4167.43 4116.15 4552.09
Total Expenditure 2890.07 2597.98 2758.65 2673.53 2889.02
Operating Profit 1510.64 1018.55 1408.78 1442.62 1663.08
Other Income 223.94 240.46 166.67 215.08 303.9
Interest 5.24 7.41 7.84 22.84 18.07
Depreciation 110.3 146.74 162.11 169.27 176.24
Exceptional Items 0 -56.46 0 0 -24.35
Profit Before Tax 1619.04 1048.4 1405.5 1465.59 1748.31
Tax 406.89 272.58 362.17 375.83 448.76
Net Profit 1212.16 775.83 1043.33 1089.75 1299.55
Adjusted EPS (Rs.) 73.78 47.11 63.34 66.14 78.88

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 16.43 16.47 16.47 16.48 16.48
Total Reserves 7141.8 7936.83 8978.82 9738.63 10793.56
Borrowings 3.82 3.26 2.55 1.11 0
Other N/C liabilities 90.15 86.42 129.05 141.64 164.16
Current liabilities 581.94 730.2 414.2 523.77 633.03
Total Liabilities 7834.14 8773.18 9541.09 10421.62 11607.21
Assets
Net Block 1502.19 1570.55 1693.73 1744.99 1688.43
Capital WIP 180.75 177.22 120.01 42.21 137.63
Intangible WIP 10 0 0 0 0
Investments 8.16 8.16 2385.74 2789.57 3292.55
Loans & Advances 286.4 128.92 114.38 77.89 66.39
Other N/C Assets 2.21 0 655.91 0 0
Current Assets 5844.44 6888.34 4571.33 5766.96 6422.22
Total Assets 7834.14 8773.18 9541.09 10421.62 11607.21
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 1619.04 1048.4 1405.5 1465.59 1748.31
Adjustment -28.19 37.38 23.15 -5.15 19.18
Changes in Assets & Liabilities -393.05 -407 23.38 -34.59 -212.86
Tax Paid -406.51 -310.89 -316.05 -352.17 -419.4
Operating Cash Flow 791.29 367.89 1135.97 1073.67 1135.23
Investing Cash Flow -1006.92 1211.22 -2917.58 1582.29 -74.03
Financing Cash Flow 34.9 14.92 -7.4 -339.54 -316.18
Net Cash Flow -180.73 1594.04 -1789.01 2316.42 745.02

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 51.83 51.83 51.83 51.83 51.77
fosun pharma industrial p... 51.83 51.83 51.83 51.83 51.77
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 48.17 48.17 48.17 48.17 48.23
dsp small cap fund - - - 1.65 1.62
government pension fund g... 1.49 1.34 1.36 1.36 1.34
hdfc mutual fund - hdfc m... 6.57 6.34 6.16 6.39 6.11
icici prudential india op... 5.08 2.79 2.87 3.09 1.79
llp 0.03 0.03 0.03 0.02 0.06
mirae asset large & midca... 6.24 6.05 6.73 6.92 5.69
nippon life india trustee... - 5.74 5.74 5.04 4.93
sbi large & midcap fund 2.91 3.16 3.10 3.29 3.32
uti-flexi cap fund 1.16 1.21 1.23 1.22 1.22
dsp healthcare fund - - 1.28 - -
nippon life india trustee... 6.11 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY26
Concall Q4FY25
Concall Q4FY23
Concall Q4FY22
Concall Q4FY21
Concall Q3FY24
Concall Q3FY22
Concall Q3FY22
Concall Q3FY21
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY21
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY23
Presentation Q2FY23
Presentation Q2FY22
Presentation Q1FY23
Presentation Q1FY22

Company News

Gland Pharma informs about appointment of chief executive officer 14 Aug, 9:39 AM Gland Pharma zooms on reporting 47% jump in Q1 consolidated net profit 11 Aug, 12:26 PM Gland Pharma reports 47% jump in Q1 consolidated net profit 11 Aug, 12:00 PM Gland Pharma - Quaterly Results 11 Aug, 12:00 AM Gland Pharma soars on executing strategic agreement with Global Pharmaceutical Company 10 Aug, 9:26 AM Gland Pharma executes strategic agreement with Global Pharmaceutical Company 10 Aug, 9:08 AM Gland Pharma gains on partnering with Neuland Laboratories 6 Aug, 10:50 AM Gland Pharma, Neuland Laboratories join forces for sterile API manufacturing 6 Aug, 10:10 AM Gland Pharma trades higher on getting USFDA’s approval for Sugammadex Injection 29 Jul, 12:53 PM Gland Pharma gets USFDA’s approval for Sugammadex Injection 29 Jul, 12:44 PM Gland Pharma informs about press release 29 Jul, 12:22 PM Gland Pharma informs about board meeting 25 Jul, 11:51 AM Gland Pharma informs about allotment of equity shares 2 Jun, 5:33 PM Gland Pharma shines on reporting jumps 97% in Q4 consolidated net profit 18 May, 2:37 PM Gland Pharma’s consolidated net profit jumps 97% in Q4 18 May, 2:21 PM Gland Pharma informs about newspaper advertisement 16 May, 12:33 PM Gland Pharma - Quaterly Results 16 May, 12:00 AM Gland Pharma informs about press release 4 Mar, 1:12 PM Gland Pharma gets USFDA’s tentative nod for Brimonidine Tartrate Ophthalmic Solution 4 Mar, 12:26 PM Gland Pharma informs about change in management 18 Feb, 5:28 PM Gland Pharma informs about analyst meet 18 Feb, 3:28 PM Gland Pharma gets USFDA’s approval for Zoledronic Acid Injection 6 Feb, 12:21 PM Gland Pharma - Quaterly Results 29 Jan, 12:00 AM Gland Pharma rises on getting nod for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) 8 Jan, 9:55 AM Gland Pharma gets nod for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) 7 Jan, 4:58 PM Gland Pharma reports 12% rise in Q2 consolidated net profit 4 Nov, 3:28 PM Gland Pharma - Quaterly Results 4 Nov, 12:00 AM Gland Pharma informs about outcome of board meeting 3 Nov, 5:11 PM Gland Pharma informs about earnings call 17 Oct, 6:09 PM Gland Pharma informs about analyst meet 17 Oct, 6:03 PM Gland Pharma informs about investor meetings 8 Sep, 4:07 PM Gland Pharma receives USFDA’s approval for Vasopressin in 5% Dextrose RTU Injection 26 Aug, 12:50 PM Gland Pharma gets USFDA’s nod for Cangrelor for Injection 12 Aug, 4:59 PM Gland Pharma gets USFDA’s approval for Norepinephrine Bitartrate 12 Aug, 3:59 PM Gland Pharma informs about press release 12 Aug, 3:13 PM Gland Pharma informs about press release 6 Aug, 3:24 PM Gland Pharma reports 50% jump in Q1 consolidated net profit 5 Aug, 5:45 PM Gland Pharma - Quaterly Results 5 Aug, 4:25 PM Gland Pharma - Quaterly Results 5 Aug, 4:25 PM Gland Pharma - Quaterly Results 5 Aug, 4:25 PM Gland Pharma informs about BRSR 31 Jul, 5:22 PM Gland Pharma gets GMP Compliance Certificate for Pashamylaram facility 14 Jul, 10:12 AM Gland Pharma gets EIR from USFDA for Visakhapatnam facility 24 Jun, 12:00 PM Gland Pharma’s subsidiary gets 11 observations for Fontenay manufacturing facility 5 Jun, 10:22 AM Gland Pharma informs about press release 4 Jun, 2:48 PM Gland Pharma submits press release 4 Jun, 10:52 AM Gland Pharma gets USFDA’s approval for Angiotensin II Acetate Injection 4 Jun, 9:12 AM Gland Pharma informs about annual secretarial compliance report 27 May, 5:09 PM Gland Pharma - Quaterly Results 20 May, 4:59 PM Gland Pharma - Quaterly Results 20 May, 4:59 PM

Gland Pharma Stock Price Analysis and Quick Research Report. Is Gland Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Gland Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Gland Pharma has a PE ratio of 35.1322516009529 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Gland Pharma has ROA of 11.7986% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Gland Pharma has a Current ratio of 10.1453.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Gland Pharma has a ROE of 12.6665%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Gland Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Gland Pharma has reported revenue growth of 10.591% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Gland Pharma for the current financial year is 36.5343231200072%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Gland Pharma is Rs 20 and the yield is 0.6737%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Gland Pharma is Rs 84.5434. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Gland Pharma in Ticker for free. Also, one can get the intrinsic value of Gland Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Gland Pharma FAQs

Q1. What is Gland Pharma share price today?
Ans: The current share price of Gland Pharma is Rs 2970.2.

Q2. What is the market capitalisation of Gland Pharma?
Ans: Gland Pharma has a market capitalisation of Rs 48998.39765022 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Gland Pharma?
Ans: The PE ratio of Gland Pharma is 35.1322516009529 and the P/B ratio of Gland Pharma is 4.4027970850406, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Gland Pharma share?
Ans: The 52-week high share price of Gland Pharma is Rs 3039.8, and the 52-week low share price of Gland Pharma is Rs 1573.6.

Q5. Does Gland Pharma pay dividends?
Ans: Currently, Gland Pharma pays dividends. Dividend yield of Gland Pharma is around 0.6737%.

Q6. What are the face value and book value of Gland Pharma shares?
Ans: The face value of Gland Pharma shares is Rs 1, while the book value per share of Gland Pharma is around Rs 674.6166. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Gland Pharma?
Ans: Gland Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Gland Pharma?
Ans: The ROE of Gland Pharma is 12.6665% and ROCE of Gland Pharma is 17.1763%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Gland Pharma a good buy for the long term?
Ans: The Gland Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Gland Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Gland Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Gland Pharma’s financials?
Ans: You can review Gland Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Gland Pharma

Gland Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Gland Pharma Ltd. is a leading pharmaceutical company in India that specializes in the production of injectables. As a long-term stock investor, it is important to analyze the company's financials and performance to make informed investment decisions.  We will discuss various aspects of Gland Pharma Ltd.'s stock analysis page, including its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Gland Pharma Ltd. Share Price

The share price of Gland Pharma Ltd. is an important factor to consider when analyzing the company's stock. It reflects the market's perception of the company's financial performance and growth prospects. Our pre-built screening tools enable investors to track the company's share price and monitor any fluctuations in real-time.

Gland Pharma Ltd. Balance Sheet

The balance sheet of Gland Pharma Ltd. provides a snapshot of the company's financial position at a specific point in time. It includes assets, liabilities, and equity. Ticker premium features allow for fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools enable investors to analyze the company's financial performance and make informed investment decisions.

Gland Pharma Ltd. Annual Report

The annual report of Gland Pharma Ltd. provides a comprehensive overview of the company's financial performance and operations over the past year. It includes information on the company's revenue, expenses, profits, and losses. Ticker provides downloadable annual reports that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Dividend

Gland Pharma Ltd. has a history of paying dividends to its shareholders. The company's dividend policy reflects its financial performance and growth prospects. Investors can use our pre-built screening tools to track the company's dividend payments and monitor any changes in the dividend policy.

Gland Pharma Ltd. Quarterly Result

The quarterly result of Gland Pharma Ltd. provides information on the company's financial performance and operations over the past quarter. It includes information on the company's revenue, expenses, profits, and losses. Ticker provides downloadable quarterly results that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Stock Price

The stock price of Gland Pharma Ltd. reflects the market's perception of the company's financial performance and growth prospects. Ticker pre-built screening tools enable investors to track the company's stock price and monitor any fluctuations in real-time.

Gland Pharma Ltd. Price Chart

The price chart of Gland Pharma Ltd. provides a visual representation of the company's stock price over a specific period. It enables investors to track the company's stock price trends and make informed investment decisions.

Gland Pharma Ltd. News

Ticker provides the latest news and updates on Gland Pharma Ltd. Investors can use this information to stay up-to-date on the company's performance and make informed investment decisions.

Gland Pharma Ltd. Concall

The concall of Gland Pharma Ltd. provides a platform for the company's management to discuss its financial performance and operations with investors. Ticker provides transcripts of the company's concalls that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Transcripts

Ticker provides transcripts of Gland Pharma Ltd. 's concalls and investor presentations. Investors can use this information to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Investor Presentations

The investor presentations of Gland Pharma Ltd. provide a comprehensive overview of the company's financial performance and operations. Ticker provides downloadable investor presentations that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Promoters

The promoters of Gland Pharma Ltd. are a group of individuals who have a significant stake in the company. They play an important role in the company's management and decision-making processes. Investors can use Ticker pre-built screening tools to track the company's promoters and monitor any changes in their stake.

Gland Pharma Ltd. Shareholders

The shareholders of Gland Pharma Ltd. are individuals or institutions who own a stake in the company. They play an important role in the company's decision-making processes. Investors can use our pre-built screening tools to track the company's shareholders and monitor any changes in their stake.

Gland Pharma Ltd. ROCE

Return on Capital Employed (ROCE) is a crucial financial metric that assesses a company's efficiency in generating profits from its capital investments. Access the ROCE data for Gland Pharma Ltd. on our stock analysis page in the financials table or ratio section. This metric provides insights into the company's capital utilization efficiency and allows for performance comparisons within the industry. Obtain the ROCE data for Gland Pharma Ltd. here.

Gland Pharma Ltd. EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a significant metric that illustrates a company's operational profitability. Find the EBITDA data for Gland Pharma Ltd. on our stock analysis page in the financials table or ratio section. Analyzing EBITDA provides insights into the company's core business profitability and its ability to generate cash flow from operations. Access the EBITDA data for Gland Pharma Ltd. here.

Gland Pharma Ltd. DPS

Dividends Per Share (DPS) represents the amount of dividends distributed to each outstanding share. Discover the DPS data for Gland Pharma Ltd. on our stock analysis page in the financials table or ratio section. The DPS data helps investors evaluate the company's dividend distribution policy and its potential as an income-generating investment. Access the DPS data for Gland Pharma Ltd. here.

Gland Pharma Ltd. EPS

Earnings Per Share (EPS) measures a company's profitability on a per-share basis, providing insights into its earnings performance and growth potential. On our stock analysis page, you can find the EPS data for Gland Pharma Ltd. in the financials table or ratio section. Analyzing the EPS enables investors to assess the company's profitability trends and make informed investment decisions. Access the EPS data for Gland Pharma Ltd. here. 

Gland Pharma's Equity and Liabilities Growth

Gland Pharma's financial stability reflects in a consistent increase in total reserves from Rs. 3,630.74 Cr. in March 2020 to a robust Rs. 8,978.82 Cr. by March 2024. The share capital has remained stable at Rs. 16.47 Cr. from March 2023 to March 2024, ensuring shareholder's equity is steady. Interestingly, the borrowings have shown an impressive decrease, indicating a stronger financial position with less reliance on debt, down from Rs. 4.07 Cr. in March 2020 to just Rs. 2.55 Cr. in March 2024.

Gland Pharma's Asset Expansion

On the assets front, Gland Pharma showcases growth in its net block, rising from Rs. 968.10 Cr. in March 2020 to Rs. 1,693.73 Cr. by March 2024. This emphasizes the company's investment in tangible assets for future productivity. Moreover, there's a significant leap in investments from a mere Rs. 0.55 Cr. in March 2021 to a substantial Rs. 2,385.74 Cr. in March 2024, potentially indicating strategic diversification or expansion.

Gland Pharma's Comprehensive Balance Sheet Analysis

Gland Pharma's overall balance sheet portrays a resilient and growing financial standing. The total liabilities of the company have expanded from Rs. 4,086.04 Cr. to Rs. 9,541.09 Cr. over the span of four years, matching the total assets to maintain a balanced sheet. Current assets have seen fluctuations but stood at Rs. 4,571.33 Cr. in March 2024. The consistencies and growth patterns reflect careful financial planning and strategic asset management.

The data provided is an analysis for the Standalone Balance Sheet of the company.

The continuous evolution in Gland Pharma's financials could be an essential factor for investors performing stock screening and evaluating market trends in the pharmaceutical sector.

Read More
X